A Meta analysis of endostar（rh-endostain，YH-16） plus chemotherapy containing platinum in the treatment of advanced non-small cell lung cancer

Abstract:

Objective：To use Meta analysis to evaluate the short term efficacy and safety of endostar plus chemotherapy in the treat－ment of advanced NSCLC，and to compare it with the chemotherapy containing platinum alone. Methods：Cochrane systematic evalu－ation was used to search literatures from VIP，CBM，WanFang Data，PubMed，CNKI，etc. on Internet.Literatures from other sources were also searched by hand. The literature quality was independently evaluated and cross-checked by four evaluators according to the Jadad scale，and the results of homogeneous studies were analysed with RevMan4.2 software. Results：11 literatures（1 012 cases） were selected to the Meta analysis，and the analysis suggested that compared to the chemotherapy containing platinum alone，the combina－tion with endostar had a statistically significant benefit in OR（overall response rate）（RR=1.89，95%CI：1.55-2.29，P<0.000 01） and CBR（clinical benefit rate）（RR=1.21，95%CI：1.12-1.30，P<0.000 01）.The combination had no statistically significant benefit in leukopenia，nausea and vomiting，liver function，kidney function and alopecia，but had statistically significant benefit in arrhythmia. Conclusion：Compared to the chemotherapy containing platinum alone，endostar plus the chemotherapy can improve OR and CBR in the treatment for the advanced non-small cell lung cancer（NSCLC）. The combination has not increased the incidence rate of ad－verse events significantly.